Trial of CF101 to Treat Patients With Psoriasis

Inclusion Criteria:

Male or female, 18 to 80 years of age, inclusive
Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area involvement ≥10%
Duration of psoriasis of at least 6 months
Physician global assessment (PGA) ≥3
Candidate for systemic treatment or phototherapy for psoriasis
Electrocardiogram (ECG) is normal
Females of child-bearing potential must have a negative serum pregnancy test
Females of child-bearing potential must be willing to use 2 methods of contraception
Ability to complete the study in compliance with the protocol
Ability to understand and provide written informed consent.

Exclusion Criteria:

Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis
Treatment with systemic retinoids, corticosteroids, or immunosuppressive agents within 4 weeks of the Baseline visit
Treatment with high potency topical corticosteroids, keratolytics, or coal tar within 2 weeks of the Baseline visit
Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit
Treatment with a biological agent within a period of time equal to 5 times its circulating half-life
Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit
Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal
Liver aminotransferase levels greater than the laboratory's upper limit of normal
Significant acute or chronic medical or psychiatric illness
Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to Screening visit.